Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.37 |
| ▸ | LMNA | P02545 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 4/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3357067 | 0.93 | ALDH1A1 (0.37) | ALDH1A1LMNAMEN1KMT2AKDM4E | |
| SCHEMBL3353090 | 0.87 | HTR4 (0.33) | KDM4EMAPTSMN1; SMN2GAA | |
| SCHEMBL4947251 | 0.86 | ALDH1A1 (0.38) | ALDH1A1LMNAMEN1KMT2AKDM4E | |
| SCHEMBL24826477 | 0.72 | RIPK1 (0.32) | — | |
| SCHEMBL7479469 | 0.72 | PIK3CD (0.42) | ALDH1A1LMNAMEN1KMT2AKDM4E | |
| SCHEMBL2989704 | 0.71 | RIPK1 (0.32) | LMNAGAA | |
| SCHEMBL15427979 | 0.70 | ALDH1A1 (0.48) | ALDH1A1LMNAMEN1KMT2ATDP1 | |
| SCHEMBL2991734 | 0.67 | NOTUM (0.43) | — | |
| Hydrochloric Acid SCHEMBL11496417 | 0.65 | ALDH1A1 (0.38) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL7485284 | 0.64 | KDM4E (0.39) | LMNAKDM4EMAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910321-A1 | NEW COMPOUNDS, PROCESS FOR THEIR PREPARATION, INTERMEDIATES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OF 5-HT6 MEDIATED DISORDERS SUCH AS ALZHEIMER'S DISEASE, COGNITIVE DISORDERS, COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA, OBESITY AND PARKINSON'S DISEASE | AstraZeneca AB (SE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007004959-A1 | NEW COMPOUNDS, PROCESS FOR THEIR PREPARATION, INTERMEDIATES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OF 5-HT6 MEDIATED DISORDERS SUCH AS ALZHEIMER'S DISEASE, COGNITIVE DISORDERS, COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA, OBESITY AND PARKINSON'S DISEASE | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | WO | disclosed |